3. Export and Quality Premiums
- Global buyers increasingly require residue-free produce,
especially in grapes, tea, and spices.
- Exporters use biostimulants to meet residue
norms in European
and North American markets
These
trends are not just policy or market abstractions—they shape real-world
decisions at the farm level. Farmers are increasingly looking for solutions
that do
more with less, improve soil health, and meet sustainability
and export standards. This is where biostimulants complement traditional
fertilizers, creating a practical path for India’s green transition.
Biostimulants
and bulk fertilizers: Partners in growth, not replacements
From farm level impact
to industry action: How indian firms are accelerating the Bio transition
The
complementary benefits of bulk fertilizers and biostimulants are not just
theoretical—they are shaping real-world strategies for agrochemical
companies and startups in India. Firms are investing in bio-based solutions
to meet farmer demand, sustainability goals, and export requirements,
translating the promise of biostimulants into scalable offerings.
With
clear policy direction and rising farmer awareness, Indian agrochemical players
are rapidly expanding their bio-based portfolios:
- UPL is scaling its
Natural Plant Protection (NPP) division globally
- Coromandel
Internationa is
investing in microbial and seaweed-based inputs under its Bio Products
Division.
- Sumitomo
Chemical India is
integrating biologicals into its broader agri-input portfolio
- Tradecorp has launched Biimore,
a next-generation biostimulant targeting fruit, legume, and horticultural
segments
Startups
are equally dynamic:
- Sea6
Energy
(funded by BASF and Tata Capital) pioneers seaweed-derived biostimulants.
- BioPrime
AgriSolutions,
backed by Omnivore, focuses on microbiome-based crop enhancers
- Absolute’s
Inera
and Varaha are leveraging data and carbon analytics to scale sustainable
agri-input adoption
Challenges
on the road to scale
Despite strong policy and market tailwinds, several challenges
continue to constrain large-scale adoption and commercialisation:
1. High compliance costs
- Stringent testing, documentation, and bio-efficacy trial
requirements increase costs
- Small and mid-sized firms struggle to meet these obligations,
leading to market exits